Christine Schmid-Tannwald to Neuroendocrine Tumors
This is a "connection" page, showing publications Christine Schmid-Tannwald has written about Neuroendocrine Tumors.
Connection Strength
3.602
-
Quantitative SSTR-PET/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM. Radiol Oncol. 2023 12 01; 57(4):436-445.
Score: 0.837
-
Neuroendocrine liver metastases treated using transarterial radioembolization: Identification of prognostic parameters at 68Ga-DOTATATE PET/CT. Diagn Interv Imaging. 2024 Jan; 105(1):15-25.
Score: 0.815
-
Apparent diffusion coefficients (ADC) in response assessment of transarterial radioembolization (TARE) for liver metastases of neuroendocrine tumors (NET): a feasibility study. Acta Radiol. 2022 Jul; 63(7):877-888.
Score: 0.709
-
[Gastroenteropancreatic endocrine tumors]. Radiologe. 2014 Oct; 54(10):989-97.
Score: 0.444
-
Comparison of abdominal MRI with diffusion-weighted imaging to 68Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreas. Eur J Nucl Med Mol Imaging. 2013 Jun; 40(6):897-907.
Score: 0.398
-
Diagnostic performance of PET/CT in the detection of liver metastases in well-differentiated NETs. Cancer Imaging. 2023 Apr 25; 23(1):41.
Score: 0.201
-
Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients. Eur Radiol. 2023 May; 33(5):3416-3424.
Score: 0.200